Approval of PreHevbrio came nearly a month after the U.S. Centers for Disease Control (CDC)’s Advisory Committee on Immunization Practices (ACIP) unanimously recommended universal HBV vaccination for all U.S. adults aged 18-59 and for adults age 60+ with risk factors for infection. According to VBI, ACIP’s vote will nearly double the U.S. HBV adult vaccination market over the next five to eight years, to more than $500 million from about $320 million in 2019 . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge